214 related articles for article (PubMed ID: 28924870)
1. Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial.
Bruna J; Videla S; Argyriou AA; Velasco R; Villoria J; Santos C; Nadal C; Cavaletti G; Alberti P; Briani C; Kalofonos HP; Cortinovis D; Sust M; Vaqué A; Klein T; Plata-Salamán C
Neurotherapeutics; 2018 Jan; 15(1):178-189. PubMed ID: 28924870
[TBL] [Abstract][Full Text] [Related]
2. Selective Blockade of the Sigma 1 Receptor Has Beneficial Effects on Both Acute and Chronic Oxaliplatin-Induced Peripheral Neuropathy.
Dorsey SG
Neurotherapeutics; 2018 Jan; 15(1):176-177. PubMed ID: 29110212
[No Abstract] [Full Text] [Related]
3. Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin-induced peripheral neurotoxicity in stage II/III colorectal cancer.
Wang DS; Wang ZQ; Chen G; Peng JW; Wang W; Deng YH; Wang FH; Zhang JW; Liang HL; Feng F; Xie CB; Ren C; Jin Y; Shi SM; Fan WH; Lu ZH; Ding PR; Wang F; Xu RH; Li YH
Cancer Med; 2020 Jan; 9(1):151-159. PubMed ID: 31724334
[TBL] [Abstract][Full Text] [Related]
4. Sigma-1 receptor: a new player in neuroprotection against chemotherapy-induced peripheral neuropathy.
Bruna J; Velasco R
Neural Regen Res; 2018 May; 13(5):775-778. PubMed ID: 29862996
[TBL] [Abstract][Full Text] [Related]
5. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
[TBL] [Abstract][Full Text] [Related]
6. Role of metformin in oxaliplatin-induced peripheral neuropathy in patients with stage III colorectal cancer: randomized, controlled study.
El-Fatatry BM; Ibrahim OM; Hussien FZ; Mostafa TM
Int J Colorectal Dis; 2018 Dec; 33(12):1675-1683. PubMed ID: 29931409
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.
Kotaka M; Saito Y; Kato T; Satake H; Makiyama A; Tsuji Y; Shinozaki K; Fujiwara T; Mizushima T; Harihara Y; Nagata N; Kurihara N; Ando M; Kusakawa G; Sakai T; Uchida Y; Takamoto M; Kimoto S; Hyodo I
Cancer Chemother Pharmacol; 2020 Nov; 86(5):607-618. PubMed ID: 32965539
[TBL] [Abstract][Full Text] [Related]
8. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.
Smith EM; Pang H; Cirrincione C; Fleishman S; Paskett ED; Ahles T; Bressler LR; Fadul CE; Knox C; Le-Lindqwister N; Gilman PB; Shapiro CL;
JAMA; 2013 Apr; 309(13):1359-67. PubMed ID: 23549581
[TBL] [Abstract][Full Text] [Related]
9. Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial.
de Andrade DC; Jacobsen Teixeira M; Galhardoni R; Ferreira KSL; Braz Mileno P; Scisci N; Zandonai A; Teixeira WGJ; Saragiotto DF; Silva V; Raicher I; Cury RG; Macarenco R; Otto Heise C; Wilson Iervolino Brotto M; Andrade de Mello A; Zini Megale M; Henrique Curti Dourado L; Mendes Bahia L; Lilian Rodrigues A; Parravano D; Tizue Fukushima J; Lefaucheur JP; Bouhassira D; Sobroza E; Riechelmann RP; Hoff PM; ; Valério da Silva F; Chile T; Dale CS; Nebuloni D; Senna L; Brentani H; Pagano RL; de Souza ÂM
Oncologist; 2017 Oct; 22(10):1154-e105. PubMed ID: 28652279
[TBL] [Abstract][Full Text] [Related]
10. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial.
Cascinu S; Catalano V; Cordella L; Labianca R; Giordani P; Baldelli AM; Beretta GD; Ubiali E; Catalano G
J Clin Oncol; 2002 Aug; 20(16):3478-83. PubMed ID: 12177109
[TBL] [Abstract][Full Text] [Related]
12. Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial.
Wang XS; Shi Q; Bhadkamkar NA; Cleeland CS; Garcia-Gonzalez A; Aguilar JR; Heijnen C; Eng C
J Pain Symptom Manage; 2019 Oct; 58(4):662-671. PubMed ID: 31254639
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.
Durand JP; Deplanque G; Montheil V; Gornet JM; Scotte F; Mir O; Cessot A; Coriat R; Raymond E; Mitry E; Herait P; Yataghene Y; Goldwasser F
Ann Oncol; 2012 Jan; 23(1):200-205. PubMed ID: 21427067
[TBL] [Abstract][Full Text] [Related]
14. Real world, open label experience with lacosamide against acute painful oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Psimaras D; Bruna J; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):178-183. PubMed ID: 32277545
[TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Kalofonos HP
J Peripher Nerv Syst; 2021 Mar; 26(1):43-48. PubMed ID: 33345432
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine for the Prevention of Oxaliplatin Induced Peripheral Neuropathy: A Randomized, Placebo-Controlled, Double-blind Clinical Trial.
Aghili M; Darzikolaee NM; Babaei M; Ghalehtaki R; Farhan F; Razavi SZE; Rezaei S; Esmati E; Samiei F; Azadvari M; Farazmand B; Bayani R; Amiri A
J Gastrointest Cancer; 2023 Jun; 54(2):467-474. PubMed ID: 35426033
[TBL] [Abstract][Full Text] [Related]
18. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double‑blind, placebo‑controlled trial of goshajinkigan to prevent oxaliplatin‑induced neuropathy.
Kono T; Hata T; Morita S; Munemoto Y; Matsui T; Kojima H; Takemoto H; Fukunaga M; Nagata N; Shimada M; Sakamoto J; Mishima H
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1283-90. PubMed ID: 24121454
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the effects of duloxetine on prophylaxis of oxaliplatin-induced peripheral neuropathy in patients with gastrointestinal cancer: A randomized double-blind placebo controlled clinical trial.
Rokhsareh S; Haghighi S; Tavakoli-Ardakani M
J Oncol Pharm Pract; 2023 Jan; 29(1):60-65. PubMed ID: 34738855
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of N-acetylcysteine on oxaliplatin-induced neurotoxicity in patients with colorectal and gastric cancers: A randomized, double blind, placebo-controlled, clinical trial.
Bondad N; Boostani R; Barri A; Elyasi S; Allahyari A
J Oncol Pharm Pract; 2020 Oct; 26(7):1575-1582. PubMed ID: 32063109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
